Kelyniam Global, Inc., ("KLYG") Announces Private Investment to Public Entity ("PIPE") Closure of Securities Offering
Kelyniam Global (OTC: KLYG), a custom cranial implants manufacturer, has completed a private placement of restricted common stock to accredited investors, closing on November 30, 2024. The offering did not include warrants. The company plans to utilize the proceeds to support its 2025 growth objectives, focusing on:
- Enhanced sales and marketing for current and pipeline products
- Regulatory and FDA filing fees for new product launches
- Geographical expansion across US neurology-focused trauma centers
CEO Ross Bjella noted strong performance in the first three quarters and expressed confidence in deploying funds to build scale across distribution channels and geographies in 2025 and beyond.
Kelyniam Global (OTC: KLYG), un produttore di impianti cranici su misura, ha completato un collocamento privato di azioni comuni restrittive per investitori accreditati, chiudendo il 30 novembre 2024. L'offerta non ha incluso warrant. L'azienda prevede di utilizzare i proventi per sostenere i propri obiettivi di crescita del 2025, concentrandosi su:
- Aumento delle vendite e del marketing per i prodotti attuali e in fase di sviluppo
- Spese per la registrazione e le richieste alla FDA per i nuovi lanci di prodotto
- Espansione geografica nei centri traumatologici focalizzati sulla neurologia negli Stati Uniti
Il CEO Ross Bjella ha osservato una performance solida nei primi tre quarti e ha espresso fiducia nell'uso dei fondi per costruire scala attraverso i canali di distribuzione e le aree geografiche nel 2025 e oltre.
Kelyniam Global (OTC: KLYG), un fabricante de implantes craneales personalizados, ha completado una colocaci贸n privada de acciones comunes restringidas para inversores acreditados, cerrando el 30 de noviembre de 2024. La oferta no incluy贸 garant铆as. La empresa planea utilizar los ingresos para apoyar sus objetivos de crecimiento para 2025, enfoc谩ndose en:
- Mejorar ventas y marketing para productos actuales y en desarrollo
- Costos de regulaci贸n y presentaci贸n ante la FDA para nuevos lanzamientos de productos
- Expansi贸n geogr谩fica en los centros de trauma enfocados en neurolog铆a en EE. UU.
El CEO Ross Bjella mencion贸 un fuerte desempe帽o en los primeros tres trimestres y expres贸 confianza en desplegar fondos para construir escala a trav茅s de canales de distribuci贸n y geograf铆as en 2025 y m谩s all谩.
Kelyniam Global (OTC: KLYG), 毵烄钉順� 霊愱皽瓿� 鞛勴攲霝�韸� 鞝滌“鞐呾泊臧� 鞚胳霅� 韴瀽鞛愲摛鞚� 雽�靸侅溂搿� 鞝滍暅霅� 氤错喌欤茧ゼ 靷頃橂姅 瓿惦毳� 鞕勲頃橃榾鞙茧┌, 2024雲� 11鞗� 30鞚检棎 膦呺霅橃棃鞀惦媹雼�. 鞚� 鞝滌晥鞚� 鞗岆煱韸鸽ゼ 韽暔頃橃 鞎婌晿鞀惦媹雼�. 須岇偓電� 2025雲� 靹膘灔 氇╉憸毳� 歆�鞗愴晿旮� 鞙勴暣 臁半嫭頃� 鞛愱笀鞚� 靷毄頃� 瓿勴殟鞚措┌, 雼れ潓鞐� 欷戩爯鞚� 霊� 瓴冹瀰雼堧嫟:
- 順勳灛 氚� 臧滊皽 欷戩澑 鞝滍拡鞚� 韺愲Г 氚� 毵堨紑韺� 臧曧檾
- 鞁犾牅頀� 於滌嫓毳� 鞙勴暅 攴滌牅 氚� FDA 鞝滌稖 靾橃垬耄�
- 氙戈淡 鞁犼步頃� 欷戩嫭鞚� 鞕胳儊 靹柬劙鞐� 雽�頃� 歆�毽爜 頇曥灔
CEO 搿滌姢 牍勳牑霛�(Ross Bjella)電� 觳� 靹� 攵勱赴 霃欖晥 臧曤牓頃� 靹标臣毳� 鞏戈笁頃橂┌ 2025雲� 氚� 攴� 鞚错泟鞚� 鞙犿喌 毂勲剱瓿� 歆�鞐棎 瓯胳箿 攴滊 頇曥灔鞚� 鞙勴暣 鞛愱笀鞚� 氚办箻頃� 靾� 鞛堧嫟電� 鞛愳嫚臧愳潉 響滊獏頄堨姷雼堧嫟.
Kelyniam Global (OTC: KLYG), un fabricant d'implants cr芒niens sur mesure, a compl茅t茅 un placement priv茅 d'actions ordinaires restreintes pour des investisseurs accr茅dit茅s, cl么turant le 30 novembre 2024. L'offre n'incluait pas de bons de souscription. L'entreprise pr茅voit d'utiliser les produits pour soutenir ses objectifs de croissance pour 2025, en se concentrant sur :
- Am茅lioration des ventes et du marketing pour les produits actuels et en d茅veloppement
- Frais r茅glementaires et frais de d茅p么t aupr猫s de la FDA pour les nouveaux lancements de produits
- Expansion g茅ographique dans les centres de trauma ax茅s sur la neurologie aux 脡tats-Unis
Le PDG Ross Bjella a not茅 une performance solide au cours des trois premiers trimestres et a exprim茅 sa confiance dans le d茅ploiement des fonds pour construire une 茅chelle 脿 travers les canaux de distribution et les r茅gions g茅ographiques en 2025 et au-del脿.
Kelyniam Global (OTC: KLYG), ein Hersteller von individuellen Sch盲delimplantaten, hat eine private Platzierung von eingeschr盲nkten Stammaktien f眉r akkreditierte Investoren abgeschlossen, die am 30. November 2024 abgeschlossen wurde. Das Angebot beinhaltete keine Optionen. Das Unternehmen plant, die Erl枚se zu nutzen, um seine Wachstumsziele f眉r 2025 zu unterst眉tzen, mit einem Fokus auf:
- Erweiterte Verkaufs- und Marketingma脽nahmen f眉r bestehende und zuk眉nftige Produkte
- Regulatorische Geb眉hren und FDA-Anmeldungen f眉r neue Produkteinf眉hrungen
- Geografische Expansion in neurologische Traumazentren in den USA
CEO Ross Bjella bemerkte eine starke Leistung in den ersten drei Quartalen und 盲u脽erte Vertrauen, dass die Mittel eingesetzt werden, um die Skalierung 眉ber Vertriebskan盲le und geografische Regionen im Jahr 2025 und dar眉ber hinaus voranzutreiben.
- Successful completion of private placement funding
- Strong performance reported for first three quarters of 2024
- Strategic expansion plans across multiple growth channels
- No warrant dilution in the offering structure
- Share dilution from new stock issuance
Proceeds to Further Growth Objectives in 2025
The company intends to use the proceeds to accelerate its 2025 growth objectives across several investments. Chief among these objectives include additional sales and marketing efforts for current and pipeline products, regulatory and FDA filing fees for new product introductions and additional geographical expansion to territories and trauma centers across
"I am pleased that our shareholders continue to express confidence in the strategic direction of Kelyniam. The first three quarters of the year have been stellar for business", said Ross Bjella, CEO of the Company. "We intend to thoughtfully deploy these funds in building scale across all of our distribution channels and geographies in 2025 and beyond."
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and craniofacial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is .
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; and changes in the status of ability to market products.
View original content:
SOURCE Kelyniam Global Inc
FAQ
What is the purpose of KLYG's 2024 private placement offering?
When did Kelyniam Global (KLYG) close its private placement offering?
How will KLYG use the proceeds from its 2024 private placement?
Were warrants included in KLYG's 2024 private placement offering?
How has KLYG's business performance been in 2024?
